Insider Selling: Shockwave Medical, Inc. (NASDAQ:SWAV) VP Sells 203 Shares of Stock
Shockwave Medical, Inc. (NASDAQ:SWAV – Get Free Report) VP Trinh Phung sold 203 shares of the firm’s stock in a transaction that occurred on Thursday, December 7th. The shares were sold at an average price of $171.63, for a total transaction of $34,840.89. Following the transaction, the vice president now directly owns 29,037 shares of the company’s stock, valued at approximately $4,983,620.31. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.
Shockwave Medical Stock Performance
Shares of SWAV stock traded down $0.89 during trading hours on Friday, reaching $174.20. The company had a trading volume of 378,626 shares, compared to its average volume of 574,356. The company has a debt-to-equity ratio of 1.22, a quick ratio of 13.19 and a current ratio of 14.43. The business has a fifty day moving average price of $189.51 and a 200-day moving average price of $231.27. Shockwave Medical, Inc. has a one year low of $157.00 and a one year high of $315.95. The firm has a market cap of $6.43 billion, a PE ratio of 27.27, a price-to-earnings-growth ratio of 9.79 and a beta of 0.87.
Shockwave Medical (NASDAQ:SWAV – Get Free Report) last announced its earnings results on Monday, November 6th. The company reported $0.92 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.81 by $0.11. The business had revenue of $186.02 million for the quarter, compared to analysts’ expectations of $184.71 million. Shockwave Medical had a return on equity of 42.41% and a net margin of 36.33%. The business’s revenue for the quarter was up 41.6% on a year-over-year basis. During the same period last year, the firm posted $0.92 earnings per share. Sell-side analysts predict that Shockwave Medical, Inc. will post 3.62 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Shockwave Medical
Institutional investors have recently bought and sold shares of the stock. Harbour Investments Inc. grew its holdings in Shockwave Medical by 3.3% during the first quarter. Harbour Investments Inc. now owns 1,300 shares of the company’s stock valued at $282,000 after purchasing an additional 41 shares during the period. Snowden Capital Advisors LLC grew its stake in shares of Shockwave Medical by 1.4% during the 1st quarter. Snowden Capital Advisors LLC now owns 3,035 shares of the company’s stock valued at $658,000 after acquiring an additional 43 shares during the period. Exchange Traded Concepts LLC increased its holdings in Shockwave Medical by 11.5% in the 3rd quarter. Exchange Traded Concepts LLC now owns 483 shares of the company’s stock worth $96,000 after acquiring an additional 50 shares in the last quarter. Lindbrook Capital LLC increased its holdings in Shockwave Medical by 64.8% in the 3rd quarter. Lindbrook Capital LLC now owns 150 shares of the company’s stock worth $30,000 after acquiring an additional 59 shares in the last quarter. Finally, Treasurer of the State of North Carolina raised its stake in Shockwave Medical by 0.4% during the 3rd quarter. Treasurer of the State of North Carolina now owns 16,390 shares of the company’s stock worth $3,263,000 after acquiring an additional 60 shares during the period. 87.35% of the stock is owned by institutional investors.
Wall Street Analysts Forecast Growth
SWAV has been the subject of a number of analyst reports. Needham & Company LLC reduced their price objective on Shockwave Medical from $265.00 to $260.00 and set a “buy” rating for the company in a research report on Tuesday, November 7th. UBS Group started coverage on Shockwave Medical in a research note on Friday, September 29th. They issued a “neutral” rating and a $218.00 target price on the stock. Leerink Partnrs reaffirmed an “outperform” rating on shares of Shockwave Medical in a research report on Monday, October 16th. Morgan Stanley dropped their price target on shares of Shockwave Medical from $284.00 to $223.00 and set an “overweight” rating on the stock in a research note on Monday. Finally, TheStreet lowered shares of Shockwave Medical from a “b-” rating to a “c+” rating in a research note on Thursday, August 10th. Two investment analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $263.00.
Read Our Latest Stock Report on SWAV
About Shockwave Medical (Get Free Report)
ShockWave Medical, Inc, a medical device company, develops intravascular lithotripsy (IVL) technology for the treatment of calcified plaque in patients with peripheral and coronary vascular, and heart valve diseases in the United States and internationally. The company offers products for the treatment of peripheral artery disease (PAD), including M5 IVL catheter and M5+ IVL catheter, which are five-emitter catheters for use in our IVL system in medium-diameter vessels; S4 IVL catheter, a four-emitter catheter for use in IVL system in small-diameter vessels; and L6 IVL catheter, a six-emitter catheter for use in IVL System in large diameter vessels.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider Shockwave Medical, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Shockwave Medical wasn’t on the list.
While Shockwave Medical currently has a “Moderate Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.
Click the link below and we’ll send you MarketBeat’s list of the 10 best stocks to own in 2024 and why they should be in your portfolio.